Product Description
Mechanisms of Action: FFA1 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: General Diabetes|Type 2 Diabetes|Kidney Failure, Chronic|Other
Phase 2: General Diabetes|Type 2 Diabetes
Phase 1: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Comparison of TAK-875 to Glimepiride in Combination with Metformin in Subjects with Type II Diabetes | P3 |
Terminated |
Type 2 Diabetes |
2016-01-27 |
|
| TAK-875_311 | P3 |
Withdrawn |
Type 2 Diabetes|Kidney Failure, Chronic |
2016-01-01 |
|
| TAK-875_306 | P3 |
Terminated |
Type 2 Diabetes |
2014-05-01 |
|
| TAK-875_302 | P3 |
Terminated |
Type 2 Diabetes |
2014-03-01 |